DiaSorin S.p.A
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, endocrinology, gastrointestinal infections, autoimmunity, hypertension, emergency/sepsis, bone metabolism, and oncology under L… Read more
DiaSorin S.p.A (DSRLF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.048x
Based on the latest financial reports, DiaSorin S.p.A (DSRLF) has a cash flow conversion efficiency ratio of 0.048x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($73.96 Million) by net assets ($1.53 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
DiaSorin S.p.A - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how DiaSorin S.p.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
DiaSorin S.p.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DiaSorin S.p.A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Navin Fluorine International Limited
NSE:NAVINFLUOR
|
0.078x |
|
Vista Energy S.A.B. de C.V.
BA:VIST
|
0.106x |
|
Materion Corporation
NYSE:MTRN
|
0.020x |
|
Keppel DC REIT
OTCGREY:KPDCF
|
0.013x |
|
Sasol Limited
PINK:SASOF
|
0.155x |
|
Axcelis Technologies Inc
NASDAQ:ACLS
|
0.044x |
|
Beijing Tricolor Technology Co Ltd
SHG:603516
|
0.031x |
|
Simmons First National Corporation
NASDAQ:SFNC
|
0.065x |
Annual Cash Flow Conversion Efficiency for DiaSorin S.p.A (2003–2024)
The table below shows the annual cash flow conversion efficiency of DiaSorin S.p.A from 2003 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.80 Billion | $358.78 Million | 0.199x | -1.59% |
| 2023-12-31 | $1.54 Billion | $311.66 Million | 0.203x | -20.90% |
| 2022-12-31 | $1.52 Billion | $389.34 Million | 0.256x | -12.53% |
| 2021-12-31 | $1.37 Billion | $400.66 Million | 0.293x | -8.03% |
| 2020-12-31 | $956.32 Million | $304.56 Million | 0.318x | +16.16% |
| 2019-12-31 | $848.62 Million | $232.67 Million | 0.274x | -7.94% |
| 2018-12-31 | $704.74 Million | $209.88 Million | 0.298x | +31.97% |
| 2017-12-31 | $741.96 Million | $167.44 Million | 0.226x | -9.59% |
| 2016-12-31 | $663.38 Million | $165.60 Million | 0.250x | +5.86% |
| 2015-12-31 | $587.16 Million | $138.45 Million | 0.236x | -4.86% |
| 2014-12-31 | $483.57 Million | $119.85 Million | 0.248x | -4.72% |
| 2013-12-31 | $414.13 Million | $107.72 Million | 0.260x | -13.42% |
| 2012-12-31 | $368.08 Million | $110.58 Million | 0.300x | -2.83% |
| 2011-12-31 | $351.18 Million | $108.58 Million | 0.309x | +1.97% |
| 2010-12-31 | $315.94 Million | $95.79 Million | 0.303x | +2.86% |
| 2009-12-31 | $217.85 Million | $64.22 Million | 0.295x | -4.90% |
| 2008-12-31 | $154.15 Million | $47.78 Million | 0.310x | +22.84% |
| 2007-12-31 | $120.27 Million | $30.35 Million | 0.252x | -34.84% |
| 2006-12-31 | $87.74 Million | $33.98 Million | 0.387x | -87.64% |
| 2005-12-31 | $6.75 Million | $21.13 Million | 3.133x | +607.13% |
| 2004-12-31 | $55.21 Million | $24.46 Million | 0.443x | +79.85% |
| 2003-12-31 | $52.58 Million | $12.95 Million | 0.246x | -- |